Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Micell Technologies Inc Company Overview 4

Micell Technologies Inc Company Snapshot 4

Micell Technologies Inc Pipeline Products and Ongoing Clinical Trials Overview 4

Micell Technologies Inc – Pipeline Analysis Overview 6

Micell Technologies Inc - Key Facts 6

Micell Technologies Inc - Major Products and Services 7

Micell Technologies Inc Pipeline Products by Development Stage 8

Micell Technologies Inc Ongoing Clinical Trials by Trial Status 10

Micell Technologies Inc Pipeline Products Overview 12

Bioresorbable Scaffold (BRS) 12

Bioresorbable Scaffold (BRS) Product Overview 12

Drug-Coated Balloon 13

Drug-Coated Balloon Product Overview 13

MiStent SES 14

MiStent SES Product Overview 14

MiStent SES Clinical Trial 15

Peripheral Drug-Eluting Stent 17

Peripheral Drug-Eluting Stent Product Overview 17

Micell Technologies Inc - Key Competitors 18

Micell Technologies Inc - Key Employees 19

Micell Technologies Inc - Locations And Subsidiaries 20

Head Office 20

Recent Developments 21

Micell Technologies Inc, Recent Developments 21

May 23, 2018: Positive Two-Year Data from MiStent DESSOLVE III Trial Presented at EuroPCR – Excellent Safety And Low Target Lesion Revascularization (TLR) Rates Persist 21

Mar 20, 2018: Micell Technologies Announces Expanded Patent Estate 22

Jan 09, 2018: Positive Five-Year Data Published for MiStent in EuroIntervention 22

Dec 06, 2017: The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent Performance in All-Comers Randomized Trial; MiStent Achieved Primary Endpoint vs Xience 22

May 16, 2017: Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience 23

Nov 28, 2016: Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial Of MiStent In Japan 24

Oct 31, 2016: Positive Five-Year Clinical Data from Micell Technologies' MiStent Presented at TCT 2016 25

Mar 22, 2016: Micell Technologies Completes Enrollment in OCT Study Designed to Evaluate Superior Performance of MiStent SES Compared to Xience 26

Feb 25, 2016: Micell Technologies Highlights Data From Published Propensity Analysis of MiStent SES and Market Standard Xience V Coronary Stent 27

Dec 09, 2015: Micell Technologies Announces Completion of Enrollment in MiStent Randomized Trial against Xience 28

Appendix 30

Methodology 30

About GlobalData 33

Contact Us 33

Disclaimer 33

Summary

Micell Technologies Inc (Micell) is a medical device company that develops drug delivery systems for the treatment of cardiovascular diseases. The company provides product such as MiStent sirolimus eluting absorbable polymer coronary stent system, a drug-eluting stent that is designed to optimize healing. It offers novel drug-coated balloon to deliver sirolimus to the artery wall at the site of a percutaneous transluminal angioplasty and stent implantation for peripheral and coronary indications. Micell provides a fluid-based technology platform to provide control over drug morphology and apply multiple therapeutic agents in single or multiple layers to achieve tailored therapeutics. The company also conducts clinical and pre-clinical trials. Micell is headquartered in Durham, North Carolina, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Micell Technologies Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company